Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Hepatocellular Carcinoma With High Risk of Recurrence”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Looking for participantsNCT07239245
What this trial is testing

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Who this might be right for
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07475026
What this trial is testing

Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Who this might be right for
HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 198
Post-approval studies (Phase 4)Looking for participantsNCT06930573
What this trial is testing

AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC
The First Affiliated Hospital of Zhengzhou University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07522411
What this trial is testing

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
BinYong Liang 100
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07014150
What this trial is testing

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Resectable
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05519410
What this trial is testing

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487662
What this trial is testing

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Sun Yat-sen University 105
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06954116
What this trial is testing

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Who this might be right for
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Tongji Hospital 26
Not applicableActive Not RecruitingNCT07009470
What this trial is testing

A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

Who this might be right for
HCC
Tongji Hospital 130
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableUnknownNCT05621499
What this trial is testing

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 60
Not applicableLooking for participantsNCT07064681
What this trial is testing

The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Who this might be right for
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Sun Yat-sen University 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07018947
What this trial is testing

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

Who this might be right for
Resectable Hepatocellular Carcinoma
Fundacion Clinic per a la Recerca Biomédica 90
Testing effectiveness (Phase 2)Study completedNCT01624285
What this trial is testing

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Who this might be right for
Adult Primary Hepatocellular CarcinomaLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer+1 more
Jonsson Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)UnknownNCT04834986
What this trial is testing

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05578430
What this trial is testing

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Who this might be right for
Resectable Hepatocellular Carcinoma
Sun Yat-sen University 54
Testing effectiveness (Phase 2)Looking for participantsNCT06812039
What this trial is testing

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Fudan University 165
Testing effectiveness (Phase 2)UnknownNCT04888546
What this trial is testing

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Who this might be right for
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
Chinese Academy of Medical Sciences 20
Testing effectiveness (Phase 2)Study completedNCT04701060
What this trial is testing

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 31